Jessica Burris, MD
she/her/hers
Assistant ProfessorDownloadHi-Res Photo
Cards
Appointments
Psychiatry
Primary
About
Copy Link
Titles
Assistant Professor
Biography
Board-certified psychiatrist with steadfast passion for both compassion and clinical excellence in patient-centered care and medical education.
Clinical areas of focus include emergency psychiatry, interventional psychiatry, and consult-liaison psychiatry.
Last Updated on September 11, 2025.
Appointments
Education & Training
- Resident
- Yale University (2023)
- MD
- Vanderbilt University School of Medicine (2019)
- BA
- University of Virginia
Board Certifications
Adult Psychiatry
- Certification Organization
- American Board of Psychiatry & Neurology
- Original Certification Date
- 2024
Research
Copy Link
Research at a Glance
Publications Timeline
A big-picture view of Jessica Burris's research output by year.
11Publications
99Citations
Publications
2024
Updated Developments in Fentanyl Use among Psychiatric Emergency Room Patients
Burris J, Fuehrlein B (2024) Updated Developments in Fentanyl Use among Psychiatric Emergency Room Patients. Emerg Med Inves 9: 10133. https://doi.org/10.29011/2475-5605.110133Peer-Reviewed Original Research
2023
Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease
Long M, Parlett L, Lewis J, Haynes K, Adimadhyam S, Hou L, Wolfe A, Toh S, Burris J, Dorand J, Kappelman M. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2023, 30: 1345-1352. PMID: 37611117, DOI: 10.1093/ibd/izad176.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInflammatory bowel diseaseAnti-tumor necrosis factor α therapyCOVID-19 complicationsMechanical ventilationBowel diseaseΑ therapyCOVID-19Users of corticosteroidsRetrospective cohort studyIncidence of hospitalizationCOVID-19 hospitalizationOutcomes of interestIBD medicationsIBD patientsOutpatient deathsCohort studyInpatient deathMedication utilizationMore hospitalizationsDecreased riskImmunosuppressed individualsMean ageTreatment codesLarge cohortCorticosteroidsReal-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
Adimadhyam S, Lewis J, Simon A, Wolfe A, Smith S, Hou L, Moyneur É, Reynolds J, Toh S, Dobes A, Parlett L, Haynes K, Burris J, Dorand J, Long M, Kappelman M. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2023, 30: 554-562. PMID: 37358904, DOI: 10.1093/ibd/izad115.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLower treatment persistenceUlcerative colitisTreatment persistenceFollowing secondary outcomesLarge US insurerFirst-line treatmentNecrosis factor inhibitorsTotal abdominal colectomyUlcerative colitis patientsAnti-TNF inhibitorsEvidence of treatmentDiverse US populationReal-world studyAbdominal colectomyCause hospitalizationThromboembolic eventsCardiac eventsCohort studyColitis patientsSecondary outcomesClinical factorsPrimary outcomeAnti-TNFPrimary cohortFactor inhibitorsComparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
Kappelman M, Long M, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Fehlmann T, Brensinger C, Haynes K, Nair V, Kaul A, Dobes A, Lewis J. Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib. Crohn's & Colitis 360 2023, 5: otad031. PMID: 37350775, PMCID: PMC10284045, DOI: 10.1093/crocol/otad031.Peer-Reviewed Original ResearchCitationsAltmetricConceptsUlcerative colitisIBD PartnersSecondary outcomesPain interferenceAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsEffectiveness of vedolizumabNecrosis factor therapyCo-primary outcomesProspective cohort studyPatient-reported outcomesSocial role satisfactionSecondary nonresponseVedolizumab usersSecondary endpointsTreatment persistenceCohort studyFactor therapyTreatment initiationBiological therapyTreatment groupsPatientsLarger sample sizeTofacitinibVedolizumabComparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab. Digestive Diseases And Sciences 2023, 68: 3413-3420. PMID: 37115362, DOI: 10.1007/s10620-023-07942-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsShort Crohn's Disease Activity IndexDisease activity indexCrohn's diseasePain interferenceCorticosteroid useTreatment persistenceSecondary outcomesAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsCrohn's Disease Activity IndexEffectiveness of vedolizumabHigher corticosteroid useLower treatment persistenceNecrosis factor therapyCo-primary outcomesPatient-reported outcomesInternet-based cohort studyLogistic regression modelsIBD PartnersCohort studyExperienced patientsFactor therapyPrimary outcomeBiological therapySteroid use
2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease
Kappelman M, Adimadhyam S, Hou L, Wolfe A, Smith S, Simon A, Moyneur É, Reynolds J, Toh S, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Dawwas G, Lewis J, Long M. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. The American Journal Of Gastroenterology 2022, 118: 674-684. PMID: 36508681, DOI: 10.14309/ajg.0000000000002068.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCrohn's diseaseCause hospitalizationCD hospitalizationsTreatment persistenceSecondary outcomesAntitumor necrosis factor therapyReal-world comparative effectiveness studiesAntitumor necrosis factorLarge US insurerNecrosis factor therapyTreatment persistence ratesAnti-TNF treatmentBaseline clinical characteristicsRetrospective cohort studyComparative effectiveness studiesRoute of administrationDiverse US populationLongitudinal claims dataRefractory populationClinical characteristicsCohort studyFactor therapyPrimary outcomePatient preferencesNecrosis factorS934 Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. S934 Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease. The American Journal Of Gastroenterology 2022, 117: e676-e676. DOI: 10.14309/01.ajg.0000860376.18652.65.Peer-Reviewed Original ResearchS738 Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease
Kappelman M, Adimadhyam S, Hou L, Simon A, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Long M. S738 Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease. The American Journal Of Gastroenterology 2022, 117: e519-e520. DOI: 10.14309/01.ajg.0000859592.38187.d3.Peer-Reviewed Original ResearchTu1436: SYSTEMIC CORTICOSTEROIDS BUT NOT ANTI-TNF ARE ASSOCIATED WITH INCREASED RISK OF HOSPITALIZATION, INTENSIVE CARE, AND DEATH AMONG PATIENTS WITH IBD: RESULTS FROM A LARGE, POPULATION-BASED COHORT
Kappelman M, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Adimadhyam S, Hou L, Wolfe A, Toh D, Burris J, Dorand J, Lewis J, Long M. Tu1436: SYSTEMIC CORTICOSTEROIDS BUT NOT ANTI-TNF ARE ASSOCIATED WITH INCREASED RISK OF HOSPITALIZATION, INTENSIVE CARE, AND DEATH AMONG PATIENTS WITH IBD: RESULTS FROM A LARGE, POPULATION-BASED COHORT. Gastroenterology 2022, 162: s-959. DOI: 10.1016/s0016-5085(22)62274-1.Peer-Reviewed Original Research
2018
Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network
Chung AE, Vu MB, Myers K, Burris J, Kappelman MD. Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network. Medical Care 2018, 56: s33-s40. PMID: 30074949, PMCID: PMC6143211, DOI: 10.1097/mlr.0000000000000771.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
Academic Achievements & Community Involvement
Copy Link
Featured
honor Yale Psychiatry Resident Teaching Award
06/15/2023Yale School of Medicine AwardYale University School of MedicineDetailsUnited Stateshonor Founder's Medal
05/10/2019Other AwardVanderbilt UniversityDetailsUnited Stateshonor Kaufman Prize in Medicine
05/10/2019Other AwardVanderbilt University School of MedicineDetailsUnited Stateshonor American Medical Women’s Association Glasgow-Rubin Citation for Academic Achievement
05/10/2019Other AwardAmerican Medical Women's AssociationDetailsUnited Stateshonor Beauchamp Prize in Psychiatry
05/09/2019Other AwardVanderbilt University Medical CenterDetailsUnited States
Honors
honor VA Connecticut Healthcare System Kindness Award
04/27/2023Hospital System AwardVA Connecticut Healthcare SystemDetailsUnited Stateshonor IBD Partners Top Citizen Scientist Award
12/03/2018National AwardPatient-Centered Research Outcomes InstituteDetailsUnited States